LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Inicio・Lista de Acciones・Incyte Corp

Incyte Corp

Abierto

Sector Salud

65.51 3.08

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

63.55

Máximo

65.58

Métricas clave
By Trading Economics
Ingresos	-614M -445M
Ventas	159M 1B
P/B Media del Sector	18.37 103.001
BPA	-1.82
Margen de beneficio	-42.75
Empleados	2,524
EBITDA	-626M -367M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+12.38 upside

Dividendos
By Dow Jones
Próximas Ganancias	29 oct 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	15B
Apertura anterior	62.43
Cierre anterior	65.51

Noticias sobre sentimiento de mercado

By Acuity

44%

56%

92 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

61.15 / 64.99 Soporte y Resistencia

Incyte Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

5 feb 2024, 16:29 UTC

Adquisiciones, fusiones, absorciones

Novartis in Lead to Acquire Cancer-Drug Maker MorphoSys, Reuters Reports

20 feb 2024, 10:30 UTC

Adquisiciones, fusiones, absorciones

An Executive Bought a Rival's Stock. The SEC Says That's Insider Trading. -- WSJ

5 feb 2024, 23:54 UTC

Adquisiciones, fusiones, absorciones

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion -- IBD

Comparación entre iguales

Cambio de precio

Incyte Corp Esperado

Precio Objetivo

By TipRanks

12.38% repunte

Estimación a 12 meses

Media 71.43 USD 12.38%

Máximo 92 USD

Mínimo 48 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Incyte Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

16 ratings

Comprar

Mantener

Vender

De acuerdo con 16 analistas que ofrecen calificaciones bursátiles a para Incyte Corp Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

61.15 / 64.99Soporte y Resistencia

Bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Sentimiento

By Acuity

92 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Incyte Corp

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.